Article Text

Download PDFPDF

4CPS-089 Risankizumab in refractory hidradenitis suppurativa to anti-TNFα: a case report
  1. F Gomez de Rueda1,
  2. R Castillejo García2,
  3. B Cancela Díez3,
  4. P Aceituno Madero4,
  5. MA Calleja Hernandez2
  1. 1Virgen Macarena Universitary Hospital, Hospital Pharmacy External Patients Unit, Seville, Spain
  2. 2Virgen Macarena Universitary Hospital, Hospital Pharmacy Unit, Seville, Spain
  3. 3San Agustin Hospital, Hospital Pharmacy Unit, Linares Jaén, Spain
  4. 4Jaén Universitary Hospital, Dermatology Unit, Jaén, Spain


Background and importance Hidradenitis suppurativa (HS) is a skin condition, especially in areas of constant friction, characterised by painful subdermal lesions that generally worsen over time and that have serious repercussions on the quality of life of patients. Risankizumab is a new anti-IL-23 (IgG1) monoclonal antibody authorised and used for moderate to severe psoriasis and with a potential effect on HS refractory to adalimumab (anti-tumour necrosis factor alpha (anti-TNFα)).

Aim and objectives To evaluate the evolution and response of risankizumab after combined treatment with adalimumab and resorcinol 15% cream in a severe and refractory HS in a 63-year-old man during 24 months of treatment.

Material and methods To evaluate the efficacy of risankizumab, the clinical response was monitored through the resolution of the lesions in the affected areas at 1, 3 and 6 months.

Results The patient was diagnosed in early 2019. After starting treatment with adalimumab (loading dose: 160 mg day 0, 80 mg day 14 and 40 mg weekly) for 2 years, adjuvant treatment with topical resorcinol 15% (twice a day) was started for the last 6 months. Finally it was decided to start treatment with risankizumab subcutaneous in January 2021 (loading dose: 150 mg day 0, 150 mg day 28 and 150 mg after every 12 weeks). Only adalimumab stopped before starting risankizumab. After 1 month of dual treatment (risankizumab and resorcinol), the patient showed a significant improvement in the skin lesions produced by HS. Two cycles after starting risankizumab the lesions had resolved by 80%. The patient was followed for the first 6 months with risankizumab.

Conclusion and relevance Risankizumab has proven to be a therapeutic alternative for the treatment of HS beyond glucocorticoids, methotrexate and anti-TNFα. The combination with resorcinol 15% cream seems to have enhanced the effect of risankizumab, although larger population studies are needed to establish itself as a therapeutic alternative. The role of the hospital pharmacists was to advise the Local Commission on the choice of anti-IL-23 among risankizumab, guselkumab and tildrakizumab, according to the reports reported. This is the first documented case in Andalusia, Spain.

References and/or acknowledgements 1. Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 2017;318:2019–2032.

Special thanks to the Dermatology Unit.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.